AbbVie Inc. (ABBV) vs Merck & Co., Inc. (MRK)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | MRK |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $65.01B |
| Revenue growth (YoY) | ▲ 8.6% | ▲ 1.3% |
| Net income | $4.23B | $18.25B |
| Gross margin | 70.2% | 74.8% |
| Diluted EPS | $2.36 | $7.28 |
| Insider net (6 mo) | +0 sh • 1 sells • 0 buys | −101.8K sh • 9 sells • 0 buys |
| Institutional owners | 65 | 67 |
| Institutional value held | $229.38B | $177.99B |
| Next earnings (est.) | Around Feb 3, 2027 | Feb 2, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company that develops, manufactures, commercializes and sells advanced therapies for some of the world's most complex and serious diseases. Read more →
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are managed principally on a product basis. Read more →
Source: SEC EDGAR.